ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

ClinicalTrials.gov ID: NCT02319005

Public ClinicalTrials.gov record NCT02319005. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Study identification

NCT ID
NCT02319005
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Alnylam Pharmaceuticals
Industry
Enrollment
206 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 90 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2014
Primary completion
Mar 29, 2017
Completion
Mar 29, 2017
Last update posted
Jul 17, 2018

2014 – 2017

United States locations

U.S. sites
41
U.S. states
22
U.S. cities
33
Facility City State ZIP Site status
Clinical Trial Site Bakersfield California
Clinical Trial Site Beverly Hills California
Clinical Trial Site La Mesa California
Clinical Trial Site Los Angeles California
Clinical Trial Site San Francisco California
Clinical Trial Site Stanford California
Clinical Trial Site Torrance California
Clinical Trial Site Aurora Colorado
Clinical Trial Site Washington D.C. District of Columbia 20037
Clinical Trial Site Washington D.C. District of Columbia 20422
Clinical Trial Site Tampa Florida
Clinical Trial Site Atlanta Georgia
Clinical Trial Site Chicago Illinois 60611
Clinical Trial Site Chicago Illinois 60612
Clinical Trial Site Chicago Illinois 60637
Clinical Trial Site New Orleans Louisiana
Clinical Trial Site Baltimore Maryland 21201
Clinical Trial Site Baltimore Maryland 21287
Clinical Trial Site Boston Massachusetts 02111
Clinical Trial Site Boston Massachusetts 02118
Clinical Trial Site Boston Massachusetts 02215
Clinical Trial Site Detroit Michigan
Clinical Trial Site Rochester Minnesota
Clinical Trial Site St Louis Missouri
Clinical Trial Site Newark New Jersey
Clinical Trial Site New York New York
Clinical Trial Site Rosedale New York
Clinical Trial Site The Bronx New York
Clinical Trial Site Durham North Carolina
Clinical Trial Site Cleveland Ohio 44106
Clinical Trial Site Cleveland Ohio 44195
Clinical Trial Site Columbus Ohio
Clinical Trial Site Philadelphia Pennsylvania 19102
Clinical Trial Site Philadelphia Pennsylvania 19104
Clinical Trial Site Charleston South Carolina
Clinical Trial Site Nashville Tennessee
Clinical Trial Site Dallas Texas
Clinical Trial Site Fort Worth Texas
Clinical Trial Site Houston Texas
Clinical Trial Site Richmond Virginia
Clinical Trial Site Seattle Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02319005, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 17, 2018 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02319005 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →